BGI, the Shenzhen genomic sequencing powerhouse, is once again proposing an IPO: this time the company intends to list two of its units, BGI Dx and BGI Tech, on the Shenzhen ChiNext exchange. A preliminary prospectus, filed in December 2015, placed a $3 billion valuation on the two subsidiaries, which have been merged. The IPO is expected to offer a 20% stake of the merged entity -- $600 million. BGI Tech provides contract sequencing to life science companies. BGI Dx offers clinical screening tests, especially non-invasive prenatal tests in China.
